Patient P-01534

Synthetic patientNBL-101 · Day 108 · 75+ · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Stable

Inflammatory state

Improving

Nutritional resilience

Stable

Discontinuation risk

55%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 49 SC-12 recommended — Supportive Compound SC-12
Day 50 Patient accepted — Started SC-12 in the companion
Day 56 GI symptom burden −19% vs expected — Supportive Compound SC-12
Day 57 GI-04 recommended — GI Support Protocol GI-04
Day 58 Patient accepted — Started GI-04 in the companion
Day 62 Tolerance state changed — Unstable → Improving
Day 66 GI symptom burden −22% vs expected — GI Support Protocol GI-04
Day 72 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days

Inflammatory activity-13
Toxicity-12
Treatment adherence+4

What helped?

Supportive Compound SC-12Day 49
Result: symptom burden −19%
GI Support Protocol GI-04Day 57
Result: symptom burden −22%

LIFE OS recommendation

Dietary Support Protocol NP-02

55%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

46.5/100

improving · -4.6 vs previous 14 d

Toxicity

Blood

27/100

improving · -8.4 vs previous 14 d

Sleep quality

Wearable

31.9/100

improving · +1.8 vs previous 14 d

Energy level

Daily log

3.3/10

improving · +0.4 vs previous 14 d

Stress level

Daily log

5.9/10

improving · -0.5 vs previous 14 d

Steps

Wearable

3,503

improving · +226 vs previous 14 d

Adherence

Companion

55.4 %

stable · -0.6 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 46 from the failing basin, 43 from restoration.

Good elements to keep

GI Support Protocol GI-04
intervention · steering +33.8
Supportive Compound SC-12
intervention · steering +31.9
Daily walks resumed
perturbation · steering +3.3

Main detractors to watch

Low butyrate capacity
hidden · steering -17.5
FUT2 non-secretor
hidden · steering -10.6
Bacteroides fragilis elevated
hidden · steering -7.4
Histamine load
perturbation · steering -7.4
Histamine load
detractor · GI +4 next day
Dietary fat load
detractor · GI +3.8 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+4detractor · 95%
Dietary fat load
+3.8detractor · 95%
Insoluble fibre
+1.6no signal · 41%
Alcohol
-1no signal · 28%
Simple carbohydrates
-0.4no signal · 15%
Spicy / capsaicin
+0.4no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 47 and rising
- WearableSleep 6.1 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 36/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓65
- WearableResting HR 75 bpm
- Wearable3,503 steps/day
- WearableShort sleep window
Inflammatory signalling ↓35
- MicrobiomeBacteroides fragilis expansion
- WearableHRV 29 ms, trending down

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3.1 · butyrate capacity 36/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 27 ms
Sleep: 5.7 h
Steps: 3,266
Resting HR: 76 bpm

Daily log: GI score 47, nutritional resilience 43, adherence 55.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01804	26%	S19	AD-05	improved	61
P-01483	25%	S14	AD-05	no change	35
P-01371	32%	S06	CR-01	improved	63
P-01442	30%	S13	CR-01	improved	61
P-01696	30%	S20	CR-01	improved	59
P-01708	30%	S07	CR-01	improved	59
P-01835	29%	S17	CR-01	improved	56
P-01388	28%	S17	CR-01	improved	59
P-01877	28%	S01	CR-01	improved	67
P-01430	27%	S05	CR-01	improved	54
P-01767	26%	S14	DT-01	no change	63
P-01342	25%	S11	DT-01	improved	48